An Expert View from Rajan Jethwa, chief executive of Ellipses Pharma.
The road to success in developing cancer treatments can, as the oncology sector knows only too well, be long and strewn with obstacles – many of them unavoidable.
Yet can we all say, hand on heart, that – across the sector – absolutely everything is being done to streamline a process that should ultimately be to the benefit of patients? The answer, I fear, is “no.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze